ly3437943 retatrutide triple agonist glp-1 gip glucagon just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric Retatrutide Research And GLP-1 Insights

She said, Once I got the results, I didnt see any follow-up options apart from some one-size fits all resources

Qiao H, Ren H, Du H, Zhang M, Xiong X, Lv R

Some users could experience a decrease in cravings, which may support weight management efforts

Im noticing that a lot of people are saying that they dont want to be on medication forever, Kumar said

American journal oftransplantation : official journal of the American Society of Transplantationand the American Society of Transplant Surgeons, 19(7), 18811887

So far, large studies have not shown a consistent or significant increase in pancreatitis risk with semaglutide, tirzepatide, or other GLP-1s compared to placebo